Results 201 to 210 of about 2,568,825 (335)

Elevated plasma complement factor H related 5 protein is associated with venous thromboembolism. [PDF]

Nat Commun, 2023
Iglesias MJ, Sanchez-Rivera L, Ibrahim-Kosta M, Naudin C, Munsch G, Goumidi L, Farm M, Smith PM, Thibord F, Kral-Pointner JB, Hong MG, Suchon P, Germain M, Schrottmaier W, Dusart P, Boland A, Kotol D, Edfors F, Koprulu M, Pietzner M, Langenberg C, Damrauer SM, Johnson AD, Klarin DM, Smith NL, Smadja DM, Holmström M, Magnusson M, Silveira A, Uhlén M, Renné T, Martinez-Perez A, Emmerich J, Deleuze JF, Antovic J, Soria Fernandez JM, Assinger A, Schwenk JM, Souto Andres JC, Morange PE, Butler LM, Trégouët DA, Odeberg J.   +42 more
europepmc   +1 more source

Recurrent structural variation, clustered sites of selection, and disease risk for the complement factor H (CFH) gene family

Proceedings of the National Academy of Sciences of the United States of America, 2018
Stuart Cantsilieris, Bradley J. Nelson, J. Huddleston, Carl A. Baker, L. Harshman, Kelsi Penewit, Katherine M. Munson, Melanie Sorensen, AnneMarie E Welch, V. Dang, F. Grassmann, A. Richardson, Robyn H. Guymer, Tina A. Graves-Lindsay, R. Wilson, B. H. Weber, P. Baird, R. Allikmets, Evan E. Eichler   +18 more
semanticscholar   +1 more source

In‐Depth Profiling Highlights the Effect of Efgartigimod on Peripheral Innate and Adaptive Immune Cells in Myasthenia Gravis

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Background Myasthenia gravis (MG) is an autoimmune disorder characterized by antibody‐mediated complement activation. Efgartigimod, a neonatal Fc receptor (FcRn) antagonist, is approved for treating generalized MG (gMG). However, its modulatory effects on upstream innate and adaptive immune cells remain largely unexplored.
Lei Jin, Liu Dong, Ying Wang, Dingxian He, Chong Yan, Jianying Xi, Haoqin Jiang, Yu Shi, Ming Guan, Chongbo Zhao, Jie Song, Sushan Luo   +11 more
wiley   +1 more source

Hypothetical LOC387715 is a second major susceptibility gene for age-related macular degeneration, contributing independently of complement factor H to disease risk.

Human Molecular Genetics, 2005
A. Rivera, S. Fisher, L. Fritsche, C. Keilhauer, P. Lichtner, T. Meitinger, B. Weber   +6 more
semanticscholar   +2 more sources

Gene and protein profiling of Dickkopf-3 and complement factor H in periodontitis and coronary artery disease. [PDF]

Front Dent Med
Mahendra J, Maharavi B, Natarajan PM, Arumugam M.   +3 more
europepmc   +1 more source

Complement factor H binds malondialdehyde epitopes and protects from oxidative stress

Nature, 2011
David Weismann, K. Hartvigsen, N. Lauer, K. Bennett, H. Scholl, P. C. Issa, M. Cano, H. Brandstätter, S. Tsimikas, C. Skerka, G. Superti-Furga, J. Handa, P. Zipfel, J. Witztum, C. Binder   +14 more
semanticscholar   +1 more source

Remote Monitoring in Myasthenia Gravis: Exploring Symptom Variability

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Background Myasthenia gravis (MG) is a rare, autoimmune disorder characterized by fluctuating muscle weakness and potential life‐threatening crises. While continuous specialized care is essential, access barriers often delay timely interventions. To address this, we developed MyaLink, a telemedical platform for MG patients.
Maike Stein, Maximilian Mönch, Meret Herdick, Frauke Stascheit, Sarah Hoffmann, Hannah Preßler, Philipp Mergenthaler, Carla Dusemund, Paolo Doksani, Haoqi Sun, Pushpa Narayanaswami, Andreas Meisel, Lea Gerischer, Sophie Lehnerer   +13 more
wiley   +1 more source

Anti-complement factor H (CFH) autoantibodies could delay pristane-induced lupus nephritis. [PDF]

Immunol Res, 2023
Li LL, Luan ZQ, Tan Y, Wang H, Yu XJ, Qu Z, Yu F, Chen M.   +7 more
europepmc   +1 more source

Shared Genetic Effects and Antagonistic Pleiotropy Between Multiple Sclerosis and Common Cancers

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Epidemiologic studies have reported inconsistent altered cancer risk in individuals with multiple sclerosis (MS). Factors such as immune dysregulation, comorbidities, and disease‐modifying therapies may contribute to this variability.
Asli Buyukkurt, Marius Ygonia, Ali Manouchehrinia, Philippe Lefrançois, Ingrid Kockum, Adil Harroud   +5 more
wiley   +1 more source

Disease Progression in Age-Related Macular Degeneration Patients Carrying Rare Variants in the Complement Factor H or Complement Factor I Genes. [PDF]

Invest Ophthalmol Vis Sci
Cinque F, de Breuk A, Mhmud H, De Jong S, Vermeulen J, Liefers B, den Hollander AI, Thee E, Colijn JM, Heesterbeek TJ, Klaver CC, Hoyng CB, Lechanteur YTE.   +12 more
europepmc   +1 more source